Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results

Theravance Biopharma (NASDAQ:TBPH) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25), Yahoo Finance reports. Theravance Biopharma had a negative return on equity of 18.97% and a negative net margin of 72.79%. The company had revenue of $14.26 million during the quarter, compared to analysts’ expectations of $15.81 million. During the same period in the prior year, the firm earned ($0.28) EPS.

Theravance Biopharma Stock Up 0.3 %

TBPH traded up $0.02 during mid-day trading on Wednesday, reaching $7.85. 3,609,332 shares of the company traded hands, compared to its average volume of 409,686. The company’s fifty day moving average price is $9.05 and its 200-day moving average price is $9.09. The stock has a market capitalization of $381.77 million, a P/E ratio of -9.22 and a beta of 0.24. Theravance Biopharma has a 52-week low of $7.69 and a 52-week high of $11.71.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now owns 335,965 shares of the company’s stock, valued at $3,023,685. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 6.90% of the company’s stock.

Analysts Set New Price Targets

TBPH has been the topic of several recent analyst reports. SVB Leerink cut Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $15.00 to $10.00 in a research note on Tuesday. Leerink Partnrs lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday. StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. BTIG Research started coverage on shares of Theravance Biopharma in a research report on Friday, April 12th. They set a “buy” rating and a $21.00 price target on the stock. Finally, HC Wainwright dropped their target price on shares of Theravance Biopharma from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.